Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ptc Therapeutics (PTCT)

Ptc Therapeutics (PTCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 5,673,151
  • Shares Outstanding, K 80,288
  • Annual Sales, $ 806,780 K
  • Annual Income, $ -363,300 K
  • EBIT $ 953 M
  • EBITDA $ 1,177 M
  • 60-Month Beta 0.48
  • Price/Sales 3.24
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 43.16% (-6.69%)
  • Historical Volatility 27.36%
  • IV Percentile 9%
  • IV Rank 7.27%
  • IV High 128.79% on 04/24/25
  • IV Low 36.45% on 01/21/26
  • Expected Move (DTE 27) 5.44 (7.70%)
  • Put/Call Vol Ratio 0.24
  • Today's Volume 1,284
  • Volume Avg (30-Day) 162
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 6,191
  • Open Int (30-Day) 4,496
  • Expected Range 65.22 to 76.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate -0.56
  • Number of Estimates 5
  • High Estimate -0.29
  • Low Estimate -1.14
  • Prior Year 10.04
  • Growth Rate Est. (year over year) -105.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
64.67 +9.26%
on 02/20/26
78.38 -9.85%
on 01/28/26
-2.41 (-3.30%)
since 01/20/26
3-Month
64.67 +9.26%
on 02/20/26
87.50 -19.25%
on 11/26/25
-5.80 (-7.59%)
since 11/20/25
52-Week
35.95 +96.55%
on 05/06/25
87.50 -19.25%
on 11/26/25
+20.28 (+40.25%)
since 02/20/25

Most Recent Stories

More News
PTC Therapeutics: Q4 Earnings Snapshot

PTC Therapeutics: Q4 Earnings Snapshot

PTCT : 70.66 (+1.09%)
PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results

– Full-year 2025 product and royalty revenue of $831M, exceeding guidance –

PTCT : 70.66 (+1.09%)
PTC Therapeutics Provides Regulatory Update on Translarna™

WARREN, N.J. , Feb. 12, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has withdrawn the New Drug Application (NDA) resubmission for Translarna™ (ataluren)...

PTCT : 70.66 (+1.09%)
PTC Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, Feb. 19, 2026

WARREN, N.J. , Feb. 5, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that the company will host a webcast conference call to report its fourth quarter and full year...

PTCT : 70.66 (+1.09%)
PTC Therapeutics Provides Update at J.P. Morgan Annual Healthcare Conference

– Strong Sephience™ (sepiapterin) launch continues with unaudited Q4 global revenue of $92.5M –

PTCT : 70.66 (+1.09%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , Jan. 8, 2026 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 2, 2026, the company approved 300 restricted stock units ("RSUs"), each representing...

PTCT : 70.66 (+1.09%)
PTC Therapeutics Announces Approval of Sephience™ (sepiapterin) for the Treatment of Children and Adults Living with Phenylketonuria (PKU) in Japan

– Indication includes all ages and the full spectrum of disease severity – – First Japan product approval for PTC –

PTCT : 70.66 (+1.09%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , Dec. 19, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Dec. 16, 2025, the company approved non-statutory stock options to purchase an aggregate...

PTCT : 70.66 (+1.09%)
PTC Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

WARREN, N.J. , Dec. 18, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that CEO Matthew B. Klein, M.D., will present at the 44 th Annual J.P. Morgan Healthcare Conference...

PTCT : 70.66 (+1.09%)
PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WARREN, N.J. , Dec. 1, 2025 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Nov. 24, 2025 , the company approved non-statutory stock options to purchase an aggregate...

PTCT : 70.66 (+1.09%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

PTC Therapeutics, Inc. is a biopharmaceutical company. It is focused on the discovery and development of orally administered, small-molecule drugs for genetic disorders, oncology and infectious disease. PTC Therapeutics, Inc. is based in South Plainfield, United States.

See More

Key Turning Points

3rd Resistance Point 81.34
2nd Resistance Point 76.81
1st Resistance Point 73.73
Last Price 70.66
1st Support Level 66.13
2nd Support Level 61.60
3rd Support Level 58.52

See More

52-Week High 87.50
Last Price 70.66
Fibonacci 61.8% 67.81
Fibonacci 50% 61.72
Fibonacci 38.2% 55.64
52-Week Low 35.95

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar